Both companies may succeed in this industry.

The company got some bad news to start 2026.

Evangeline Lilly has spent over twenty years portraying iconic heroes on screen, but her most daunting challenge is currently ...

We expect to launch Mounjaro in new markets outside the U.S. and Europe throughout the year. Mounjaro international revenue will contribute to overall performance more significantly in the second part ...

Eli Lilly has skyrocketed due to its strength in the high-growth obesity drug market. One biotech company in particular may ...

By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...

Shares of GPU titan Nvidia (NASDAQ:NVDA) may have been stuck in a sideways channel for the past six months, but a lot has ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

It feels like a great rotation out of the Magnificent Seven has already kicked off just over a quarter ago. Undoubtedly, the ...

If you needed proof that Gordon Gekko's greed philosophy is alive and well in 2026, look no further than the pharmaceutical ...

In December, Novo Nordisk announced that the Food and Drug Administration had approved its once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. It remains the only ...